An investigational antibody–drug conjugate (ADC) consisting of a monoclonal antibody linked to a camptothecin-derived topoisomerase I inhibitor. It binds a tumor-associated surface antigen on SCLC cells, is internalized, and releases the payload to cause DNA damage and tumor cell death, with potential bystander effect.